EXT1

Across TCGA pan-cancer cohorts, EXT1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated EXT1 data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EXT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated EXT1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, LSCC, and GBM are the cancer types where EXT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.233	0.639	.012	16	view →
LSCC	DFS	Median	II,III,IV	0.303	1.000	<.001	15	view →
GBM	DFS	Median	All	0.833	0.522	.006	6	view →
LUAD	OS	Median	II,III,IV	0.503	0.771	.024	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

EXT1–PDAC (DFS)

Open the PDAC breakdown →